Larimar Therapeutics, Inc. (LRMR) shareholders
LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.02+0.32 (+11.85%)
Close on Nov 13, 2026Market cap $313.73MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
91.9%
95M of 104M shares
Institutional holders
163
33 new, 29 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
15 buys · 0 sales
Net bought $26.10M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Deerfield Management Company, L.P. Joint filing with James E. Flynn (34.41%), Deerfield Mgmt IV, L.P. (10.25%) and 7 more | 35,667,474 | 34.41% | 13D (active) amendment | Feb 27, 2026 |
| Blue Owl Capital Holdings LP | 10,739,492 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Israel A. Englander Joint filing with Millennium Management LLC (5.80%), Millennium Group Management LLC (5.80%) | 4,966,831 | 5.80% | 13G (passive) amendment | Sep 30, 2025 |
| Opaleye, L.P. Joint filing with Opaleye Management, Inc. (6.17%), James Silverman (6.17%) | 3,952,409 | 6.17% | 13G (passive) | Apr 9, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LRMR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 35,606,974 | 34.28% | $108.60M | – | 1.13% |
| Blue Owl Capital Holdings LP | 9,163,157 | 8.82% | $27.95M | +2,043,150 | 4.21% |
| BlackRock, Inc. | 5,678,035 | 5.47% | $17.32M | +1,925,835 | 0.00% |
| Defilade Capital Management, L.P. | 3,670,135 | 3.53% | $11.19M | New | 1.50% |
| Driehaus Capital Management LLC | 3,163,423 | 3.05% | $9.65M | +229,024 | 0.06% |
| Vanguard Capital Management LLC | 2,974,901 | 2.86% | $9.07M | +108,552 | 0.00% |
| Rtw Investments, LP | 2,565,999 | 2.47% | $7.83M | +1,065,999 | 0.07% |
| Aqr Capital Management LLC | 2,371,414 | 2.28% | $7.23M | +1,553,897 | 0.00% |
| Marshall Wace, Llp | 2,012,458 | 1.94% | $6.14M | +1,078,994 | 0.00% |
| DAFNA Capital Management LLC | 2,008,164 | 1.93% | $6.12M | −21,000 | 1.17% |
| Goldman Sachs Group Inc | 1,752,910 | 1.69% | $5.35M | +191,325 | 0.00% |
| Geode Capital Management, LLC | 1,679,003 | 1.62% | $5.12M | +570,242 | 0.00% |
| Qube Research & Technologies Ltd | 1,641,042 | 1.58% | $5.01M | +793,398 | 0.00% |
| Citadel Advisors LLC | 1,456,825 | 1.40% | $4.44M | +937,693 | 0.00% |
| State Street Corp | 1,411,804 | 1.36% | $4.31M | +500,478 | 0.00% |
| Vanguard Portfolio Management LLC | 1,403,172 | 1.35% | $4.28M | +996,614 | 0.00% |
| Woodline Partners LP | 1,400,850 | 1.35% | $4.27M | – | 0.01% |
| Millennium Management LLC | 1,333,037 | 1.28% | $4.07M | −2,292,241 | 0.00% |
| Dimensional Fund Advisors LP | 961,083 | 0.93% | $2.93M | +162,621 | 0.00% |
| FMR LLC | 937,368 | 0.90% | $2.86M | +873,798 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 163 | 95M | 91.9% | 33 / 68 | 41 / 29 | 21M | 14M |
| Q1 2026 | 162 | 88M | 84.5% | 43 / 59 | 41 / 15 | 26M | 8M |
| Q4 2025 | 136 | 73M | 70.0% | 22 / 45 | 44 / 19 | 6M | 18M |
| Q3 2025 | 136 | 86M | 82.3% | 30 / 60 | 26 / 9 | 28M | 4M |
| Q2 2025 | 116 | 62M | 60.1% | 30 / 43 | 24 / 17 | 12M | 10M |
| Q1 2025 | 103 | 61M | 58.6% | 16 / 33 | 32 / 28 | 6M | 8M |
| Q4 2024 | 116 | 63M | 61.1% | 22 / 43 | 33 / 27 | 4M | 4M |
| Q3 2024 | 123 | 64M | 61.9% | 25 / 40 | 35 / 8 | 6M | 4M |
| Q2 2024 | 107 | 65M | 62.9% | 24 / 40 | 34 / 21 | 6M | 4M |
| Q1 2024 | 104 | 64M | 61.4% | 41 / 34 | 22 / 5 | 27M | 2M |
| Q4 2023 | 69 | 40M | 38.1% | 8 / 23 | 25 / 3 | 5M | 1M |
| Q3 2023 | 65 | 39M | 37.3% | 8 / 18 | 24 / 8 | 3M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
133 funds held LRMR in Q2 2026, 62% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LRMR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,206,446 | 2.12% | $6.73M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,724,694 | 1.66% | $5.26M | 0.01% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 814,618 | 0.78% | $2.48M | 0.04% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 757,603 | 0.73% | $2.31M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 726,517 | 0.70% | $2.78M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 699,471 | 0.67% | $2.13M | 0.00% | Jun 30, 2026 |
| Vanguard Explorer Fund | 659,133 | 0.63% | $2.52M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 625,151 | 0.60% | $1.91M | 0.01% | Jun 30, 2026 |
| iShares Biotechnology ETF | 370,517 | 0.36% | $1.13M | 0.01% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 340,789 | 0.33% | $1.30M | 0.01% | Jul 31, 2026 |
| Driehaus Micro Cap Growth Fund | 338,986 | 0.33% | $1.03M | 0.17% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 243,097 | 0.23% | $845.98K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 223,612 | 0.22% | $682.02K | 0.04% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 218,451 | 0.21% | $760.21K | 0.00% | May 31, 2026 |
| JPMorgan Small Cap Value Fund | 183,018 | 0.18% | $558.20K | 0.04% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Carole Ben-Maimon | President and CEO, Director | 417,482 | 0.40% | Nov 12, 2026 |
| Michael Celano | Chief Financial Officer | 234,245 | 0.23% | Nov 12, 2026 |
| John B. Harlow Jr. | President and COO | 67,800 | 0.07% | Nov 12, 2026 |
| Gopi Shankar | Chief Development Officer | 81,443 | 0.08% | Nov 12, 2026 |
| Russell Clayton | Chief Medical Officer | 71,443 | 0.07% | Jan 27, 2026 |
| Joseph Truitt | Director | 6,250 | 0.01% | Nov 12, 2026 |
| Thomas Edward Hamilton | Director | 944,231 | 0.91% | Nov 12, 2026 |
| Frank E. Thomas | Director | 15,000 | 0.01% | Nov 12, 2026 |
| Deerfield Management Company, L.P. | Director, 10% owner | 1,714,104 | 1.65% | May 20, 2026 |
| Jeffrey W. Sherman | Director | 5,000 | 0.00% | May 20, 2026 |
| Jonathan S. Leff | Director | – | – | May 20, 2026 |
| James E. Flynn | Director, 10% owner | – | – | May 20, 2026 |
| Deerfield Healthcare Innovations Fund, L.P. | Director, 10% owner | – | – | Mar 2, 2026 |
| Deerfield Mgmt IV, L.P. | Director, 10% owner | 5,830,249 | 5.61% | Mar 2, 2026 |
| Deerfield Private Design Fund IV, L.P. | Director, 10% owner | – | – | Mar 2, 2026 |
| Mgmt L.P. Deerfield | Director, 10% owner | 24,009,751 | 23.11% | Mar 2, 2026 |
| Deerfield Partners, L.P. | Director, 10% owner | – | – | Mar 2, 2026 |
| Deerfield Mgmt III, L.P. | Director, 10% owner | – | – | Mar 2, 2026 |
| Deerfield Private Design Fund III, L.P. | Director, 10% owner | – | – | Mar 2, 2026 |
| Deerfield Mgmt HIF, L.P. | Director, 10% owner | 35,606,974 | 34.28% | Mar 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Thomas Edward Hamilton Director | Nov 12, 2026 | Buy | +70,000 | $2.67 | $187.08K | 70,000 |
| Frank E. Thomas Director | Nov 11, 2026 | Buy | +8,000 | $2.73 | $21.80K | 15,000 |
| Carole Ben-Maimon President and CEO, Director | Nov 11, 2026 | Buy | +18,050 | $2.77 | $49.95K | 386,326 |
| Joseph Truitt Director | Nov 11, 2026 | Buy | +3,500 | $2.80 | $9.79K | 6,250 |
| John B. Harlow Jr. President and COO | Nov 11, 2026 | Buy | +17,800 | $2.80 | $49.92K | 67,800 |
| Michael Celano Chief Financial Officer | Nov 11, 2026 | Buy | +18,460 | $2.71 | $49.99K | 234,245 |
| Gopi Shankar Chief Development Officer | Nov 11, 2026 | Buy | +5,000 | $2.71 | $13.55K | 81,443 |
| John B. Harlow Jr. President and COO | Sep 29, 2026 | Award | +50,000 | – | – | 50,000 |
| Thomas Edward Hamilton Director | Jul 6, 2026 | Buy | +50,000 | $3.34 | $167.00K | 714,798 |
| Thomas Edward Hamilton Director | Feb 27, 2026 | Buy | +100,000 | $5.00 | $500.00K | 664,798 |
| Jeffrey W. Sherman Director | Feb 27, 2026 | Buy | +5,000 | $5.00 | $25.00K | 5,000 |
| Frank E. Thomas Director | Feb 27, 2026 | Buy | +5,000 | $5.00 | $25.00K | 7,000 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Feb 27, 2026 | Buy | +1,084,012 | $5.00 | $5.42M | 10,622,957 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Feb 27, 2026 | Buy | +831,978 | $5.00 | $4.16M | 8,153,107 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Feb 27, 2026 | Buy | +2,000,000 | $5.00 | $10.00M | 6,207,982 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Feb 27, 2026 | Buy | +1,084,010 | $5.00 | $5.42M | 10,622,928 |
| Russell Clayton Chief Medical Officer | Jan 26, 2026 | Award | +25,637 | – | – | 71,443 |
| Carole Ben-Maimon President and CEO, Director | Jan 26, 2026 | Award | +100,100 | – | – | 368,276 |
| Gopi Shankar Chief Development Officer | Jan 26, 2026 | Award | +25,637 | – | – | 76,443 |
| Michael Celano Chief Financial Officer | Jan 26, 2026 | Award | +37,604 | – | – | 215,785 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Jul 31, 2025 | Buy | +2,599,932 | $3.20 | $8.32M | 7,321,129 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Jul 31, 2025 | Buy | +3,387,539 | $3.20 | $10.84M | 9,538,945 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Jul 31, 2025 | Buy | +3,387,529 | $3.20 | $10.84M | 9,538,918 |
| Michael Celano Chief Financial Officer | Jan 22, 2025 | Award | +34,185 | – | – | 178,181 |
| Gopi Shankar Chief Development Officer | Jan 22, 2025 | Award | +23,306 | – | – | 50,806 |
| Russell Clayton Chief Medical Officer | Jan 22, 2025 | Award | +23,306 | – | – | 45,806 |
| Carole Ben-Maimon President and CEO, Director | Jan 22, 2025 | Award | +91,000 | – | – | 387,208 |
| Thomas Edward Hamilton Director | Feb 16, 2024 | Buy | +57,208 | $8.74 | $500.00K | 564,798 |
| Mgmt L.P. Deerfield Director, 10% owner | Feb 16, 2024 | Buy | +1,430,205 | $8.74 | $12.50M | 4,207,982 |
| Mgmt L.P. Deerfield Director, 10% owner | Feb 16, 2024 | Buy | +1,430,206 | $8.74 | $12.50M | 6,151,389 |
| Mgmt L.P. Deerfield Director, 10% owner | Feb 16, 2024 | Buy | +1,430,206 | $8.74 | $12.50M | 6,151,406 |
| Frank E. Thomas Director | Feb 14, 2024 | Buy | +2,000 | $11.00 | $22.00K | 2,000 |
| Gopi Shankar Chief Development Officer | Jan 17, 2024 | Award | +22,500 | – | – | 27,500 |
| Russell Clayton Chief Medical Officer | Jan 17, 2024 | Award | +22,500 | – | – | 22,500 |
| Carole Ben-Maimon President and CEO, Director | Jan 17, 2024 | Award | +66,125 | – | – | 332,954 |
| Michael Celano Chief Financial Officer | Jan 17, 2024 | Award | +31,250 | – | – | 143,996 |
| Gopi Shankar Chief Development Officer | Dec 7, 2023 | Buy | +5,000 | $3.73 | $18.65K | 5,000 |
| Joseph Truitt Director | May 17, 2023 | Buy | +2,750 | $3.73 | $10.26K | 2,750 |
| Carole Ben-Maimon President and CEO, Director | May 17, 2023 | Buy | +5,000 | $3.71 | $18.55K | 266,829 |
| Michael Celano Chief Financial Officer | May 17, 2023 | Buy | +5,000 | $3.73 | $18.65K | 112,746 |
| Michael Celano Chief Financial Officer | Jan 31, 2023 | Award | +76,000 | – | – | 107,746 |
| Carole Ben-Maimon President and CEO, Director | Jan 31, 2023 | Award | +205,000 | – | – | 261,829 |
| Thomas Edward Hamilton Director | Sep 16, 2022 | Buy | +317,460 | $3.15 | $1,000.00K | 507,590 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Sep 16, 2022 | Buy | +2,777,777 | $3.15 | $8.75M | 2,777,777 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Sep 16, 2022 | Buy | +2,777,777 | $3.15 | $8.75M | 4,721,197 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Sep 16, 2022 | Buy | +2,777,777 | $3.15 | $8.75M | 4,721,183 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Sep 16, 2022 | Buy | +2,777,777 | $3.15 | $8.75M | 4,721,200 |
| Michael Celano Chief Financial Officer | Sep 16, 2022 | Buy | +31,746 | $3.15 | $100.00K | 31,746 |
| Carole Ben-Maimon President and CEO, Director | Sep 16, 2022 | Buy | +31,746 | $3.15 | $100.00K | 56,829 |
| Deerfield Mgmt IV, L.P. Director, 10% owner | Jun 30, 2021 | Buy | +228,571 | $8.75 | $2.00M | 1,943,423 |
| Deerfield Mgmt IV, L.P. Director, 10% owner | Jun 30, 2021 | Buy | +228,569 | $8.75 | $2.00M | 1,943,406 |
| Deerfield Mgmt IV, L.P. Director, 10% owner | Jun 30, 2021 | Buy | +228,570 | $8.75 | $2.00M | 1,943,420 |
| Thomas Edward Hamilton Director | Jun 30, 2021 | Buy | +56,710 | $8.75 | $496.21K | 190,130 |
| Chondrial Therapeutics Holdings, Llc 10% owner | Jun 26, 2020 | Other | −6,091,242 | – | – | 8 |
| Carole Ben-Maimon President and CEO, Director | Jun 26, 2020 | Other | +25,083 | – | – | 25,083 |
| Thomas Edward Hamilton Director | Jun 26, 2020 | Other | +133,420 | – | – | 133,420 |
| Thomas Edward Hamilton Director | Jun 26, 2020 | Other | +159,433 | – | – | 292,853 |
| Robert J. Perez Director | Jan 24, 2019 | Award | +4,423 | $4.38 | $19.37K | 5,322 |
| John L. Lamattina Director | Jan 24, 2019 | Award | +10,844 | $4.38 | $47.50K | 31,376 |
| Atlas Venture Associates VII, L.P. 10% owner | Jun 29, 2018 | Other | −1,126,546 | – | – | 3,506,184 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
30.27%
11M shares short
Days to cover
8.3
At 1M shares a day
Change since last report
-28.1%
From 15M shares
Short volume, 20 days
52.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Larimar Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 49,053 shares on Oct 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Barrett Peter Officer | Jul 24, 2023 | 8,300 | $26.81K | Jul 24, 2023 | STOCK OPTION EXERCISE |
See a number that looks wrong?